文献速递癫痫

局灶性皮质发育不良相关癫痫儿童的药物难治性患病率及危险因素

Prevalence and Risk Factors for Pharmacoresistance in Children With Focal Cortical Dysplasia-Related Epilepsy.
PubMed 文献 · Neurology · 2022-10-31

该回顾性单中心队列研究纳入143例3T MRI确诊的局灶性皮质发育不良(FCD)患儿,其中124例(87%)患癫痫,92例(74%)符合药物难治性标准。仅1种抗癫痫发作药物失败与药物难治性风险大幅增加及更早出现相关(OR 346;95% CI 19.6-6100),而FCD脑叶位置、病理亚型及癫痫发作起病年龄经Cox回归未显示关联。作者支持将FCD相关癫痫的药物难治性操作性地重新定义为1种抗癫痫发作药物失败,并支持早期潜在治愈性手术。

要点

  • 143例FCD患儿中124例(87%)患癫痫,其中92例(74%)符合药物难治性标准。
  • 仅1种抗癫痫发作药物失败与药物难治性风险大幅增加相关(OR 346;95% CI 19.6-6100)。
  • 82例接受癫痫手术的患儿中59例(72%)术后无发作。

核心结论

  • 仅1种抗癫痫发作药物失败与药物难治性 substantial 风险相关;作者认为这些数据支持将FCD相关癫痫的药物难治性操作性地重新定义为1种抗癫痫发作药物失败以用于手术规划,并支持早期潜在治愈性手术以改善该患者群体的结局。

研究设计与样本

  • 回顾性单中心队列设计,通过集中放射报告数据库和集中癫痫手术数据库检索患者。
  • 纳入标准为2011年1月至2020年1月期间3T MRI确诊的FCD、MRI时年龄0天至22岁、MRI后至少18个月有记录的随访(除非仅有单次发作或偶然发现FCD)。
  • 排除影像或病史中存在双重病理(内侧颞叶硬化除外)、半侧巨脑畸形或结节性硬化症的患者。
  • 共143例确诊FCD患者符合纳入标准。

主要发现

  • 143例FCD患者中124例(87%)患癫痫,癫痫发作起病年龄中位数2.7岁(IQR 0.75-6岁,范围0-17岁)。
  • 12例(8.5%)仅有单次一生中发作(诱发或非诱发)或反复诱发发作;7例(4.9%)为偶然发现FCD。
  • 124例癫痫患者中92例(74%)符合药物难治性标准。
  • 所有类型癫痫患儿中93例(75%)在末次访视时无发作;82例接受癫痫手术,其中59例(72%)达到无发作。
  • 7%(9/124)通过第二种抗癫痫发作药物达到无发作,5.6%(7/124)通过第三种或更多抗癫痫发作药物达到无发作。

关键数值与推荐

  • 药物难治性定义为符合药物难治性标准,124例癫痫患者中92例(74%)符合。
  • 仅1种抗癫痫发作药物失败与药物难治性风险相关(OR 346;95% CI 19.6-6100)。

临床怎么用

  • 作者认为这些数据支持将FCD相关癫痫的药物难治性操作性地重新定义为1种抗癫痫发作药物失败以用于手术规划,并支持早期潜在治愈性手术以改善该患者群体的结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Focal cortical dysplasia (FCD) is the most common cause of surgically remediable epilepsy in children. Little is known about the risk factors for the timing and development of pharmacoresistance in this population. This study sought to evaluate the prevalence and risk factors for pharmacoresistance in pediatric FCD-related epilepsy. METHODS: In this retrospective single-center cohort design, patients were identified from search of centralized radiology report database and a central epilepsy surgical database. Inclusion criteria consisted of 3T MRI-confirmed FCD from January, 2011, to January, 2020; ages 0 days to 22 years at MRI; and at least 18 months of documented follow-up after MRI, unless had single seizure or incidentally discovered FCD. Records were excluded if there was dual pathology (except for mesial temporal sclerosis), hemimegalencephaly, or tuberous sclerosis complex present in imaging or history. RESULTS: One hundred forty-three patients with confirmed FCD met the inclusion criteria. One hundred twenty-four children had epilepsy (87% of patients with FCD) with median age at seizure onset 2.7 years (IQR 0.75-6 years, range 0-17 years). Twelve children (8.5%) had a single lifetime seizure (provoked or unprovoked) or recurrent provoked seizures. Seven children (4.9%) had incidental FCD. Ninety-two patients (74%) of those with epilepsy met criteria for pharmacoresistance. Of children with epilepsy of all types, 93 children (75%) were seizure-free at the last visit; 82 patients underwent epilepsy surgery, of whom 59 (72%) achieved seizure freedom. Seven percent (9/124) achieved seizure freedom with a second ASM and 5.6% (7/124) with a third or more ASMs. Failure of only 1 antiseizure medication is associated with enormous increased incidence and earlier development of pharmacoresistance (OR 346; 95% CI 19.6-6,100); Cox regression showed FCD lobar location, pathologic subtype, and age at seizure onset are not. DISCUSSION: Failure of 1 antiseizure medication is associated with substantial risk of pharmacoresistance. These data support an operational redefinition of pharmacoresistance, for surgical planning, in FCD-related epilepsy to the failure of 1 antiseizure medication and support early, potentially curative surgery to improve outcomes in this patient population.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Cohen NT, Chang P, You X, et al. Prevalence and Risk Factors for Pharmacoresistance in Children With Focal Cortical Dysplasia-Related Epilepsy. Neurology. 2022. PMID: 35985831. doi:10.1212/WNL.0000000000201033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。